雌激素和多巴胺对大鼠垂体组织中雌激素受体基因表达的影响

目的研究雌激素和多巴胺激动剂对雌激素受体在大鼠垂体组织表达的作用。方法20只成年雌性Wistar大鼠,切除卵巢后,随机分2组：（1）对照组（n=5）,皮下植入空白硅胶管;（2）雌激素组（n=15）皮下植入含有乙烯雌酚的硅胶管,8周后,两组各处死5只大鼠,雌激素组剩余大鼠（n=10）取出硅胶管,随机再分2组,安慰剂组（n=5）给予自来水灌胃,多巴胺组（n=5）给予溴隐亭（多巴胺激动剂）灌胃,用药4周后处死动物。放免法测定血清PRL水平,用反转录一聚合酶链反应（RT-PCR）方法检测ERs在各组垂体组织中的表达,以β-actin作为内参照,借助于计算机凝胶成像系统分析表达量。结果ERa,ERβ以及TERP在各组大鼠垂体组织均有表达,其中ERα和TERPmRNA水平在雌激素组明显高于对照组（P〈0．001）,在安慰剂组和多巴胺组的表达无明显差别。结论大鼠垂体组织中存在ER的表达,雌激素对ERα和TERP的表达具有升调节作用,多巴胺不影响雌激素受体的表达。     

褪黑素通过减弱催乳素基因增强子的突变抑制大鼠垂体催乳素瘤的增生

本工作旨在探讨褪黑素(melatonin,MLT)抑制17-β-雌二醇(17-β-estradiol,E2)诱发的Sprague-Dawley大鼠垂体催乳素(prolactin,PRL)瘤增生的分子机制。结果表明,每只大鼠每日定时皮下注射一定剂量的MLT(0.25、0.50mg)能显著抑制E2诱发的大鼠垂体PRL瘤的增生;偏低(0.05mg)或过高剂量(1.00、2.00mg)的MLT也抑制PRL瘤的增生,但无统计学意义。采用PCR和DNA直接测序显示,与正常垂体对照组比较,PRL瘤中PRL基因增强子出现五处突变,-1885bp位点由C突变为G,-1857~-1855由ACA替换为G,-1792~-1791插入G,-1383~-1382插入GGTGTGTG片段,-1265~-1250缺失GTGTGTGTGTGTGTGT片段。0.25mg/dMLT处理组,PRL瘤中的PRL基因增强子上述个别突变部位仍然存在(-1885由C突变为G),突变消失(-1792~-1791无插入G),大部分表现为突变减弱(-1856~-1855缺失AC,-1385~-1384缺失TG,-1250~-1253缺失GTGT)。采用荧光素酶报告基因检测PRL基因增强子活性显示,正常垂体、PRL瘤和0.25mg/dMLT处理的PRL瘤三组中,PRL基因增强子的活性分别为(13448.17±3012.74)、(161831.67±60996.01)和(10212.17±2634.71)OD单位。PRL瘤组增强子活性较正常垂体升高11倍(P<0.001),MLT处理组增强子活性较PRL瘤组降低93.69%(P<0.001)。上述三组PRL基因增强子空间结构的分析表明,PRL基因增强子DNA的曲折程度为PRL瘤组>MLT处理组>正常垂体。以上结果证实,MLT抑制大鼠垂体PRL瘤增生的重要分子机制之一可能是减弱PRL基因增强子的突变,也提示MLT可减弱PRL基因增强子的突变,从而下调PRL基因的高表达,可能与降低DNA的曲折程度有关。     

益坤宁对围绝经期大鼠下丘脑雌激素受体表达的影响

目的检测益坤宁对围绝经期大鼠下丘脑雌激素受体（estrogen receptor,ER）表达的影响,探讨益坤宁治疗围绝经期综合征的作用机制。方法采用自然衰老的围绝经期大鼠,随机分为围绝经期对照组、西药对照组和中药实验组;另取5月龄青年雌性大鼠做青年对照组。各组大鼠分别连续灌胃给予生理盐水、利维爱、中药益坤宁和生理盐水4周。通过免疫组化观察大鼠下丘脑ER蛋白的表达部位;Western blot定量检测大鼠下丘脑ERα和ERβ蛋白表达。结果ERα、ERβ蛋白主要表达于细胞胞质中。围绝经期对照组与青年组相比,ERa、E邓蛋白表达量明显下降（P〈0．05,P〈0．01）;中药实验组与围绝经期对照组比较,ERα、ERB蛋白表达量均明显增多（P〈0．05,P〈0．01）;西药对照组与围绝经期对照组相比,ERα、ERβ蛋白表达量增多（P〈0．05）。结论益坤宁通过提高围绝经期大鼠下丘脑组织中ERα、ERβ蛋白表达水平,使ER的合成增加,从而提高雌激素靶组织中ER的含量以增强雌激素的生物活性而发挥治疗作用。     

中药降乳散对大鼠催乳素瘤表达Pit-1的作用

目的研究中药降乳散对大鼠催乳素（PRL）瘤组织表达Pit-1的作用。方法用皮下植入雌激素的方法制备大鼠PRL瘤模型,将成功诱发出PRL瘤的大鼠随机分2组,分别给予安慰剂和中药降乳散灌胃,用药4周后处死动物,垂体称重,用放免法测定血清PRL水平。用反转录-PCR方法分析Pit-1在大鼠PRL瘤组织中的表达量。结果降乳散组大鼠血清PRL水平和垂体重量均明显低于安慰剂组（P〈0.001）,Pit-1 mRNA水平在降乳散组较安慰剂组明显降低（P〈0.001）。结论降低Pit-1的表达水平可能是中药降乳散抗PRL瘤的重要机制之一。     

转录因子E2F-1与垂体肿瘤转化基因（PTTG）在大鼠PRL瘤中的表达

目的通过检测垂体肿瘤转化基因（PTTG）与腺病毒E2启动子结合因子1（E2F-1）在大鼠催乳素（PRL）瘤中的表达来探讨两者在PRL瘤发生发展过程中的作用。方法 40只大鼠随机分为两组：实验组（E组,n=20）：皮下植入17β-雌二醇的方法诱发大鼠PRL瘤;对照组（C组,n=20）：皮下植入空白硅胶管。雌激素诱导10周后处死大鼠,心脏穿刺取血,4%多聚甲醛体内灌流取出脑垂体,称重,ELISA方法检测两组大鼠血清PRL水平,垂体组织行病理组织学观察,免疫组化SP方法检测两组大鼠垂体组织中PTTG蛋白质、E2F-1蛋白质的表达。结果雌二醇作用10周后,据垂体重量、垂体组织学变化和血清PRL水平证实PRL瘤诱导成功。PRL瘤组中,PTTG蛋白质、E2F-1蛋白质均明显高于对照组,差异具有统计学意义（P〈0.01）;且PTTG蛋白质和E2F-1蛋白质的表达呈明显正相关（γ=0.764,P〈0.01）。结论 PTTG与E2F-1在大鼠PRL瘤中共同过度表达,参与了大鼠PRL瘤的发生发展。     

大豆异黄酮对老龄大鼠雌激素水平和子宫雌激素受体表达的影响

目的探讨大豆异黄酮（soy isoflavones,SIF）对老龄大鼠雌激素水平和雌激素受体表达的影响。方法将40只16月龄雌性SD大鼠随机分为高、中和低剂量大豆异黄酮3个实验组（H-SIF,M-SIF和L-SIF）和1个对照组,每天分别按1005、0和25 mg/（kg.bw）剂量的大豆异黄酮进行灌胃,对照组灌服生理盐水。42 d后称重,股动脉放血处死动物收集血清、摘取子宫称重并冷冻保存。采用放射免疫法测定血清中雌二醇（E2）、睾酮（T）、泌乳素（PRL）、促黄体生成素（LH）和促卵泡激素（FSH）的含量;RT-PCR检测子宫雌激素受体α（ERα）基因的表达。结果与对照组相比,3个实验组血清中E2和PRL都升高,LH和FSH都降低,其中高剂量组差异有显著性（P〈0.05）;子宫重量无明显差异;子宫ERα表达呈下降趋势,但无统计学意义。结论大豆异黄酮能调节老龄大鼠血清中的雌激素水平,且有剂量依赖性;大豆异黄酮对老年大鼠子宫重量和子宫ERα的表达无影响。     

过表达ER恢复雌激素对子宫内膜癌KLE细胞中Notch信号通路的调控

目的：通过观察雌激素对子宫内膜癌KLE细胞中Notch信号通路的影响,探讨过表达雌激素核受体（estrogenreceptor,ER）是否可以恢复雌激素对Notch信号通路的调控作用,继而调节细胞增殖活性。方法：MTT检测雌激素及Notch信号通路对细胞增殖活性的影响;RT．PCR及Westem．blotting检测雌激素及Notch通路抑制剂DAPT对Notch表达的影响;质粒的抽提及转染使KLE细胞中的雌激素核受体ER过表达。结果：雌激素呈剂量依赖效应促进KLE细胞的增殖活性,其中以雌激素浓度为1．0×10-9M时最明显（相对于对照组为1．25±0．026,P〈0．05）;抑制Notch信号通路的表达可以明显下调KLE细胞的增殖活性（0．76±0．02,P〈0．05）;在KLE细胞中,雌激素对Notch的表达没有明显的调控作用,但是将其雌激素核受体过表达后,雌激素可明显上调Notch的表达,并显著促进细胞的增殖活性（1．24±0．02,P〈0．05）。结论：在ER阴性的子宫内膜癌细胞中过表达ER,可以恢复雌激素对Notch信号通路的调控,从而进一步的调控细胞增殖活性。     

无蹼壁虎心脏雌激素受体免疫组织化学研究

目的：观察雌激素受体（ERα和ERβ）在非繁殖期成年无蹼壁虎（Gekko swinhonis）心脏的表达并比较性别差异。方法：应用显示雌激素受体的免疫组织化学方法。结果：ERα和ERβ阳性反应均见于无蹼壁虎心肌细胞和成纤维细胞,且受体的表达无性别差异;ERα表达存在明显的心房（11．56±1．67）心室（6．68±1．88）差异（P〈0．01）。结论：雌激素可能是通过ERα主要作用于心房,通过ERβ调节整个心脏的机能;雌激素受体含量与性别无关,可能与生理条件下受体的活性及功能状态有关。     

雷洛昔酚对大鼠垂体的作用

目的 观察雷洛昔酚是否能诱发出催乳素瘤的动物模型以及对PRL水平的影响,以研究雷洛昔酚对大鼠垂体的作用.方法 雌性Wistar大鼠切除卵巢后,分别在皮下埋植含有雷洛昔酚、雌激素和空白硅胶管,术后8周处死大鼠,检测大鼠体重变化、垂体重量变化、血清催乳素(PRL)水平和垂体组织学变化.结果 雷洛昔酚组与阴性对照组大鼠体重无明显统计学差异,与雌激素组大鼠体重具有统计学差异(P＜0.05);雷洛昔酚组与阴性对照组大鼠垂体重相比无明显差异,与雌激素组大鼠垂体重相比具有统计学差异(P＜0.05);雌激素组大鼠血清PRL水平最高,阴性对照组血清PRL水平最低,雷洛昔酚组介于两者之间,分别与雌激素组、对照组相比较差异均具有统计学意义(P＜0.05);雷洛昔酚组与对照组垂体病理为正常细胞形态,雌激素组垂体病理为PRL瘤表现.结论 雷洛昔酚对大鼠垂体有一定的影响,但不能诱发催乳素瘤.     

褪黑素抑制雌二醇诱致的垂体PRL瘤生长与血浆PRL和过氧化脂质含量的关系

雄性大鼠皮下埋置17-β雌二醇(17-β-estradiol,E2)药泵诱发垂体催乳素PRL)瘤,并每日皮下注射褪黑素(melatonin,MLT)观察MLT对E2诱发PRL瘤生长的影响.另外,采用放免法和紫外分光光度法测定大鼠血浆PRL和过氧化脂质(peroxidativelipid,PL)浓度,观察PRL瘤重量与大鼠血浆浓度间的相关关系.实验结果显示,在对照组、0.05、0.25、0.50、1.00和2.00mgMLT组,PRL瘤重量分别为115.0±71.0、85.2±41.0、58.9±24.1、72.7±23.6、79.3±56.1、74.5±46.8mg;血浆PRL浓度分别为493.46±33.3、373.78±26.5、125.13±13.3、201.79±11.2、418.88±41.3、281.94±36.4ng/ml;血浆PL水平分别为1.21±0.23、0.89±0.32、0.92±0.27、0.64±0.24、0.41±0.14、0.43±0.21△D233/ml.相关性分析表明,PRL瘤重量与血浆PRL浓度间的相关系数为0.8738(P＜0.05),与血浆PL水平间的相关系数为0.5550(P＞0.05),血浆PRL浓度与血浆PL水平间的相关系数为0.2141(P＞0.05).该结果提示,(1)0.25(P＜0.01)、0.50(P＜0.05)mgMLT能有效抑制E2诱致的PRL瘤生长和PRL分泌,所有剂量的MLT均能抑制血浆PL的形成;(2)PRL瘤重量与血浆PRL浓度间呈正相关关系,PRL瘤重量与血浆PL水平间、以及血浆PRL浓度与血浆PL水平间均无相关关系.因此,我们认为,MLT抑制E2诱致的PRL瘤生长可能与MLT抑制PRL表达性分泌有关,但与MLT抗氧化作用无关.     

Excretion of radiolabeled estradiol metabolites in the slow loris (Nycticebus coucang)

The excretion pattern of estradiol was studied in the slow loris Nycticebus coucang) and the ring-tailed lemur (Lemur catta) in order to compare steroid excretion in two representative prosimian species. Daily urinary estrone conjugate measurements in the female loris provided little information when applied over prolonged periods. As a result of these negative data, a metabolic study was performed to determine if estrogen excretion patterns in the slow loris differed from those in the lemur, where urinary assays proved a useful tool in characterizing reproductive cycles. Radio-labeled estradiol was injected intravenously, and serial urine and fecal collections were analyzed for radiolabeled metabolites. The results of these studies demonstrate that more than 92% of the radiolabel was excreted in the feces of the loris, in contrast to only 16% excreted in the feces of the lemur.     

Excretion of radiolabeled estradiol in the cat (Felis catus,L): A preliminary report

The time course and end products of estradiol metabolism were studied in the domestic cat, which has been chosen as a model for steroid metabolism studies in nondomestic felidae. Radiolabeled estradiol was injected intravenously into three adult female cats; one had a spontaneous estrus, one was induced with follicle-stimulating hormone, and one had been ovariohysterectomized; feces, urine, and blood were collected daily, and the radioactivity content was determined. Feces and urine contained 47 and 1% of the injected dose (0.33 μCi), respectively. Metabolites appeared earlier in the urine than in feces (d 1 vs d 2 postinjection), and excretion was completed on d 5; no radioactivity was detected in plasma 24 h postinjection. Estradiol metabolites were excreted as unconjugated estrogens (22%) and as conjugates hydrolyzable with β-glucuronidase and acid solvolysis (7 and 50%, respectively); the remaining 14% were not recoverable with any of the above methods. The major portion of the conjugates was estradiol-17β (64–80%) while 11–16% appeared as estrone. Endogenous cycles related to the spontaneous and induced ovarian activity were monitored by observation of estrous behavior, vaginal epithelium cornification, and plasma estradiol determination. The reproductive state of each animal had no effect on the time course or type of metabolite excreted. We found low proportions of injected radioactivity excreted in the urine and high residual levels remaining after hydrolysis and extraction in the feces. These findings suggest that although feces are an abundant source of estradiol metabolite in the cat, and probably in the exotic felidae, development of noninvasive methods for monitoring ovarian cycles in these species will depend on more efficient methods for urine hydrolysis, on the resolution of problems encountered in fecal steroid analysis, or on the identification of metabolites which may be measured directly in the urine without hydrolysis or extraction.     

雌激素信号通路概述

过去几十年,人们一直认为雌激素信号通路是雌激素与细胞核中的雌激素受体(ER)结合,作用于雌激素受体反应元件调节基因表达,从而改变细胞功能。雌激素不但与核ER结合,也能与膜ER结合激活PI3K信号通路。G蛋白偶联受体(GPR30)也能与雌激素结合,激活PI3K信号通路。雌激素通过结合不同雌激素受体改变细胞生理功能。我们对雌激素信号通路做简要综述。     

Membrane associated estrogen receptors and related proteins: Localization at the plasma membrane and the endoplasmic reticulum

The female sex steroid, estradiol 17, mediates its effect through its association with estrogen receptor present in the target cell. So far the major emphasis has been given to the genomic actions of the hormone mediated by the nuclear estrogen receptors. Recent years have seen a shift in the ideas revealing the existence of estradiol binding entities both in the plasma membrane and the endoplasmic reticulum. Though the true identity of this membrane associated receptors is far from being known, a functional role for the same have been implicated both at the genomic as well as the non-genomic level. The major focus of the review is to highlight the existence of membrane associated estrogen receptors and receptor-related proteins and the functional roles played by some of them. The signalling events exerted by this class of membrane associated estrogen receptor could partly explain the physiological significance of estrogen in cardiovascular disease, osteoporosis and breast cancer as well as the molecular mechanism associated with xenoestrogen action.     

Developmental effects of estrogenic chemicals are predicted by an in vitro assay incorporating modification of cell uptake by serum

Many estrogenic chemicals found in the environment (xenoestrogens) show a lower affinity for plasma estrogen binding proteins relative to the natural estrogens such as estradiol. These binding proteins, which include alphafetoprotein in rats and mice, sex hormone binding globulin in humans, and albumin in all species, regulate estrogen uptake into tissues. Therefore, the in vivo estrogenic potency relative to estradiol of xenoestrogens that show lower binding to these serum proteins will thus be underestimated in assays that compare the potency of xenoestrogens to estradiol and do not take serum binding into account. We have examined the effects of the binding components in serum on the uptake of a number of xenoestrogens into intact MCF-7 human breast cancer cells. Since most estrogenic chemicals are not available in radiolabeled form, their uptake is determined by competition with [³H]estradiol for binding to estrogen receptors (ER) in an 18-h assay. Serum modified access (SMA) of cell uptake of xenoestrogens is calculated as the RBA in serum-free-medium ÷ the RBA in serum, and the bioactive free fraction of xenoestrogen in serum is then also calculated. We predicted the concentration of two xenoestrogens, bisphenol A and octylphenol, required to alter development of the prostate in male mouse fetuses. Whereas octylphenol was predicted to be a more potent estrogen than bisphenol A when tested in serum-free medium, our assay predicted that bisphenol A would be over 500-times more potent than octylphenol in fetal mice. The finding that administration of bisphenol A at a physiologically relevant dose predicted from our in vitro assay to pregnant mice from gestation day 11 to 17 increased adult prostate weight in male offspring relative to controls (similar to the effect of estradiol), while the same doses of octylphenol did not alter prostate development, provided support for our hypothesis.     

雌激素受体β潜在磷酸化位点突变体的构建及其活性测定

目的：构建雌激素受体（ER）β潜在磷酸化位点突变体,并在人胚肾细胞293T中检测其对ERβ下游基因转录的影响。方法：通过ERα和ERβ序列同源性比对,寻找ERβ的潜在磷酸化位点;以pcDNA3-ERβ-FLAG为模板,通过重组PCR,将ERβ264位、469位Ser编码基因突变为Ala编码基因,将突变片段连接到同样双酶切的pcDNA3-FLAG载体中,Western blot检测其表达;将重组质粒转入293T细胞中,检测突变体对含雌激素应答元件（ERE）的报告基因转录活性的影响。结果：ERα和ERβ序列同源性比对发现ERβ的264位Ser和469位Ser可能是其潜在的磷酸化位点;构建了ERβ264位和469位2个点突变体载体pcDNA3-FLAG-ERβ（S264A）和pcDNA3-FLAG-ERβ（S469A）,Western blot可检测到ERβ突变体融合蛋白在293T细胞中表达。萤光素酶活性检测表明,在没有雌激素刺激的情况下,2个突变体的活性较野生型没有变化;加入雌激素后,突变体的活性较野生型略有升高。结论：ERβ的264位和469位Ser位点的磷酸化可能不是ERβ调节下游基因转录所必需的,活性升高可能是由于ERβ构象变化造成的。